In the Press

COVID-19 remdesivir study finds long hospital stay, but context matters

Remdesivir, the only antiviral fully approved for COVID-19 treatment by the US Food and Drug Administration (FDA), was associated with a longer hospital stay yet no improvement in survival rates, according to a real-world observational study of military veterans today in JAMA Network Open.


Spain: Q fever confirmed in Biological Mechanical Treatment plant employees in Bilbao

At least three cases of Q fever have been confirmed among workers at the Biological Mechanical Treatment (TMB) plant located in the Bilbao area of ​​Artigas, as this newspaper has learned.


China Reports Human H5N6 Avian Influenza Death In Guangxi

Hong Kong health officials are monitoring a human case of avian influenza A(H5N6) in Guangxi in southern China. The case involved a 50-year-old man living in Hechi in Guangxi.


New pediatric asthma yardstick has treatment guidance for children of every age

Although about 10 percent of school-aged children in the United States have asthma, there are few comprehensive U.S. guidelines for treating pediatric asthma.


Study finds variation in antibiotic access, OTC use in Asia and Africa

An assessment of community antibiotic use in six low- and middle-income countries (LMICs) in Asia and Africa indicates that antibiotics are frequently obtained without a prescription, more so in Asia than Africa.


Risk factors and on-site simulation of environmental transmission of SARS-CoV-2 in the largest wholesale market of Beijing, China

Abstract From June 11, 2020, a surge in new cases of coronavirus disease 2019 (COVID-19) in the largest wholesale market of Beijing, the Xinfadi Market, leading to a second wave of COVID-19 in Beijing, China.


Report: Economy rebound hinges on race between vaccines, variants

International economic projections have improved over the past months, but faster and more effective vaccine deployment is critical for getting key sectors back to prepandemic levels, the Organization for Economic Cooperation and Development (OECD) said in its latest update.


CARB-X IS FUNDING AFFINIVAX TO DEVELOP A NOVEL VACCINE TO PREVENT STAPHYLOCOCCUS AUREUS BACTERIAL INFECTIONS

(BOSTON) – CARB-X is funding Affinivax, a Cambridge, Massachusetts, USA, biotech, to develop a new vaccine that will prevent Staphylococcus aureus (S. aureus) bacterial infections, healthcare-associated


Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract

Introduction While secondary pneumococcal pneumonia occurs less commonly after COVID-19 than after other viral infections, it remains unclear whether other interactions occur between SARS-CoV-2 and Streptococcus pneumoniae.


none 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM 08:00 AM - 05:00 PM others https://g.page/r/CcoVFDGYiftXEAg/review https://www.facebook.com/Healthy-Builds-West-Palm-106299645058480/reviews/?ref=page_internal